Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-021567
Filing Date
2022-11-03
Accepted
2022-11-03 08:00:37
Documents
75
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q rgnx-20220930.htm   iXBRL 10-Q 3449572
2 EX-31.1 rgnx-ex31_1.htm EX-31.1 15497
3 EX-31.2 rgnx-ex31_2.htm EX-31.2 15494
4 EX-32.1 rgnx-ex32_1.htm EX-32.1 15838
  Complete submission text file 0000950170-22-021567.txt   12818390

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rgnx-20220930.xsd EX-101.SCH 66261
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT rgnx-20220930_cal.xml EX-101.CAL 59966
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rgnx-20220930_lab.xml EX-101.LAB 499084
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT rgnx-20220930_def.xml EX-101.DEF 223175
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rgnx-20220930_pre.xml EX-101.PRE 368593
69 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20220930_htm.xml XML 3119313
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37553 | Film No.: 221356320
SIC: 2836 Biological Products, (No Diagnostic Substances)